Immunologic abnormalities in myelodysplastic syndromes: Clinical features and characteristics of the lymphoid population

Medical Oncology

Volumn 23, Issue 3, 2006, Pages 385-391

  Marisavljević, Dragomir ^a   Kraguljac, Nada ^a   Rolović, Zoran ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Clinical significance; Immunologic abnormalities; Incidence; Myelodysplastic syndromes; Prognosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL TRAIT; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; INCIDENCE; LYMPHOCYTOPENIA; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; SEX DIFFERENCE; SURVIVAL; T LYMPHOCYTE;

EID: 33749388952     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:3:385     Document Type: Article

References (24)

1. Knox S, Greenberg B, Anderson R, Rosenblatt L. Studies of T-lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations. Blood 1983; 61(3): 449-455.
2. Symeonidis A, et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 1991; 47: 277-281.
3. Takagi S, Kitagawa S, Takeda A, Minato N, Takaku F, Miura Y. Natural killer-interferon system in patients with preleukaemic states. Br J Haematol 1984; 58(1): 71-81.
4. Ayanlar-Batuman O, Shevitz J, Traub UC, Murphy S, Sajewski D. Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome. Blood 1987; 70(2): 494-500.
5. Baumann M, Milson T, Patrick C, Libnoch J, Keller R. Immunoregulatory abnormalities in myelodysplastic disorders. Am J Hematol 1986; 22(1): 17-26.
6. Mufti G, Galton D. Myelodysplastic syndromes: Natural history and features of prognostic importance. Clin Haematol 1986; 15: 953-974.
7. Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol 1995; 55(1): 42-48.
8. Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997; 24(5-6): 483-489.
9. Saif M, Hopkins J, Gore S. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002; 43(11): 2083-2092.
10. Copplestone J, Mufti G, Hamblin T, Oscier D. Immunological abnormalities in myelodysplastic syndromes. II Coexistent lymphoid or plasma cell neoplasia: a report of 20 cases unrelated to chemotherapy. Br J Hematol 1986; 63: 149-159.
11. Hamblin T. Immunological abnormalities in myelodysplastic syndromes. Sem Hematol 1996; 33(2): 150-162.
12. Bennett J, Catovsky D, Flandrin G, Galton D, Gralnick H, Sultan C. The French-American-British (FAB) cooperative group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
13. Reizenstein P, Ost A. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res 1992; 16(1): 3-11.
14. Iscove N, Sieber F, Winterhalter K. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirements of erythropoietin by gel filtration and affinity chromatography on agarose- concavalin A. J Cell Physiol 1974; 83: 309-315.
15. Messner H, Jamal N, Izaguirre C. The growth of large megakaryioocyte colonies from human bone marrow. J Cell Physiol Suppl 1982; 1: 45-51.
16. Novak A, Kruškić M, Ludoški M, Jurkovski V. Rapid method for obtaining high quality chromosome banding in the study of hemopoietic neoplasia. Cancer Genet Cytogenet 1994; 74(6): 109-114.
17. ISCN. Ed. Mitelman F (ed). An International System for Human Genetic Nomenclature. Karger, Basel, 1995.
18. Suvajdžić N, Marisavljević D, Jovanović V, Pantić M, Šefer D, Čolović M. Pure red cell aplasia evolving through the hyperfibrotic myelodysplastic syndrome to the acute myeloid leukemia: some pathogenetic aspects. Hematol Cell Ther 1999; 41: 27-29.
19. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
20. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100(7): 2292-2302.
21. Economopoulos T, Stathakis N, Foudoulakis A, et al. Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur J Haematol 1987; 38(4): 338-344.
22. Kerkhofs H, Hermans J, Haak HL, Leeksma CH. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987; 65(1): 73-81.
23. Hokland P, Kerndrup G, Griffin J, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986; 67: 898-902.
24. Iwase O, Aizawa S, Kuriyama Y, Yaguchi M, Nakano M, Toyama K. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. Ann Hematol 1995; 71(6): 293-299.